Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment

Bibliography

• HELLSTRAND K, HERMODSSON S: Histamine H2-receptor-mediated regulation of human natural killer cell activity. Immurrol (1986) 137:656–660.
   Google Scholar
• ••Key paper describing work done onhistamine and natural killer cells that laid the foundation for future clinical studies with histamine.
   Google Scholar
• HANSSON A, ASEA A, ERSSON U, HERMODSSON S, HELLSTRAND K: Induction of apoptosis in MK cells by monocyte-derived reactive oxygen metabolites. I Immunol (1996) 156:42–47.
   PubMed Web of Science ®Google Scholar
• HELLSTRAND K, HERMODSSON S: Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Irm Arch. Allergy Appl. Immurrol (1990) 92:379–389.
   PubMedGoogle Scholar
• ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.1 Clin. Omni (1999) 17(7):2105–2116.
   Google Scholar
• •Summarises results of high-dose bolus use of IL-2 in metastatic melanoma.
   Google Scholar
• HILL S: International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev (1997) 49(3):253–278.
   Google Scholar
• HALLER 0, HANSSON M, KIESSLING R, WIGZELL H: Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature (1977) 270:609–611.
   PubMed Web of Science ®Google Scholar
• HANNA N, BURTON R: Definitive evidence that natural killer (NK) cells inhibit experimental tumour metastasis in vivo. Immurrol (1981) 127:1754–1758.
   Google Scholar
• HERSEY E HOBBS A, EDWARDS A, McCARTHY W McGOVERN V: Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumour in melanoma patients. Cancer Res. (1982) 42:363–368.
   PubMed Web of Science ®Google Scholar
• SCHANTZ S, BROWN B, LIRA E, TAYLOR D, BEDDINGFIELD N: Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immurrol Immunother. (1987) 24:141–145.
   Google Scholar
• HORIGUCHI S, PETERSSON M, NAKAZAWA T et al.: Primary chemically induced tumours induce profound immunosuppression concomitant with apoptosis and alteration ion signal transduction in T cells and NK cells. Cancer Res. (1999) 59:2950–2956.
   PubMed Web of Science ®Google Scholar
• EREMIN 0, COOMBS R, ASHBY J: Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br .j Cancer (1981) 44:166–176.
   PubMed Web of Science ®Google Scholar
• MIZOGUCHI H, O'SHEA JJ, LONGO DL, LOEFFLER CM, MC VICAR DW, OCHOA AC: Alterations in signal transduction molecules in T lymphocytes from tumour-bearing mice. Science. (1992) 258:1795–1798.
   PubMed Web of Science ®Google Scholar
• KOREN H, ANDERSON S, FISCHER D, COPELAND C, JENSEN P: Regulation of human natural killing The role of monocytes, interferon, and prostaglandins. Immurrol. (1981) 127:2007–2013.
   Google Scholar
• SHAU H, SIDNEY G: Inhibition of lymphokine-activated killer- and natural killer- mediated cytotoxicities by neutrophils. J.Immunol. (1989) 143:1066–1072.
   PubMed Web of Science ®Google Scholar
• SEAMAN W, GINDHART T, BLACKMAN M, DALAL B, TALAL N, WERB Z: Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes. J. OM. Invest. (1982) 69:876–888.
   PubMed Web of Science ®Google Scholar
• ELGERT KD, ALLEVA DG, MULLINS DW: Tumour-induced immune dysfunction: the macrophage connection. I Leukocyte Biol. (1998) 64:275–290.
   PubMed Web of Science ®Google Scholar
• BROCKER EB, ZWADLO G, SUTER L, BRUNE M, SORG C: Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother. (1987) 25:81–86.
   PubMed Web of Science ®Google Scholar
• BROCKER EB, ZWALDO G, HOLZMANN B, MACHER E, SORG C: Inflammatory cell infiltrates in human melanoma at different stages of tumour progression. Intl Cancer (1988) 41:562–567.
   PubMed Web of Science ®Google Scholar
• HEIDL G, DAVARIS E ZWADLO G etal.: Association of macrophages detected with monoclonal antibody 25F9 with progression and pathobiological classification of gastric carcinoma. I Cancer Res. Clin Oncol (1987) 113:567–572.
   Google Scholar
• ALLEN C, HOGG N: Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology (1985) 55:289–299.
   PubMed Web of Science ®Google Scholar
• LEEK RD, LEWIS CE, WHITEHOUSE R, GREENALL M, CLARKE J, HARRIS AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. (1996) 56:4625–4629.
   PubMed Web of Science ®Google Scholar
• HANSSON J, HERMODSSON S, BRUNE M et al.: Histamine protects T cells and natural killer calls against oxidative stress. Interfer. Cytokin. Res. (1999) 19:1135–1144.
   PubMed Web of Science ®Google Scholar
• HELLSTRAND K, ASEA A, DAHLGREN C, HERMODSSON S: Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. Immurrol. (1994) 153:4940–4947.
   Google Scholar
• HELLSTRAND K, HERMODSSON S: Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scam/. Immurrol (1991) 34:741–752.
   Google Scholar
• NAKAGOMI H, PETERSSON M, MAGNUSSON I etal.: Decreased expression of the signal-transducing zeta chains in tumour-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. (1993) 53:5610–5612.
   Google Scholar
• OTSUJI M, KIMURA Y, AOE T, OKAMOTO Y, SAITO T: Oxidative stress by tumour-derived macrophages suppresses the expression of CD3 zeta chain in T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA (1996) 93:13119–13124.
   PubMed Web of Science ®Google Scholar
• KONO K, SALAZAR-ONFRAY F, PETERSSON M et al: Hydrogen peroxide secreted by tumour-derived macrophages down-regulates signal-transducing zeta molecules and inhibits tumour-specific T cell- and natural killer cell-mediated cytotoxicity. Eur. I Immunol (1996) 26:1308–1313.
   PubMed Web of Science ®Google Scholar
• DELVES PJ, ROITT IM: The immune system. First of two parts. N Engl. J. Med. (2000) 343(1):37–49.
   PubMed Web of Science ®Google Scholar
• TRINCHIERE G, PERUSSIA B: Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today (1985) 6:131–136.
   PubMedGoogle Scholar
• HOUZE TA, LARSSON P-A, HELLSTRAND K etal.: The role of reactive oxygen metabolites in the transcriptional regulation of the IFN-7 gene expression by histamine in NK cells following IL-2 stimulation. Cell Biol. Int. (1996) 20:589–598.
   Google Scholar
• OKAMOTO H, NAKANO K: Regulation of interleukin-1 synthesis by histamine produced by mouse peritoneal macrophages per se. Immunology (1990) 69(1):162–165.
   PubMed Web of Science ®Google Scholar
• WANG KY, ARIMA N, HIGUCHI S et al:Switch of histamine receptor expression from H2 to H1 during differentiation of monocytes into macrophages. FEBS Lett. (2000) 437(3):345–348.
   Google Scholar
• ROSSI F. The 02- -forming NADPH oxidase of the phagocyte: nature, mechanisms of activation and function. Biochem. Biophys. Acta (1986) 853(1):65–89.
   PubMed Web of Science ®Google Scholar
• UOTILA P: The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother (1996) 43(1):1–9.
   PubMed Web of Science ®Google Scholar
• CARON G, DELNESTE Y, ROELANDTS E et al: Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol (2001) 166(10):6000–6006.
   PubMed Web of Science ®Google Scholar
• STEINMAN RIVI: Dendritic cells and immune-based therapies. Exp. Hematol (1996) 24(8):859–862.
   PubMed Web of Science ®Google Scholar
• FEARNLEY DB, WHITE LE CARNOUTOS SA etal.: Monitoring dendritic cell numbers in normal individuals and in stem cell transplantation. Blood (1999) 93(2):728–736.
   Google Scholar
• YOUNG JW, STEINMAN RM: Dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells (1996) 14(4):376–387.
   PubMed Web of Science ®Google Scholar
• HART DN: Dendritic cells: unique leukocyte population which control the primary immune response. Blood (1997) 90(9):3245–3287.
   PubMed Web of Science ®Google Scholar
• BUZAID AC, ROSS MI, BALCH CM et al.: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J. Clin. Oncol. (1997) 15(3):1039–1051.
   PubMed Web of Science ®Google Scholar
• CORONA R, MELE A, AMINI D etal.: Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J. Clin. Oncol. (1996) 14(4):1218–1223.
   Google Scholar
• BALCH CM, BUZAID AC, ATKINS MB et al: A new American Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 88(6):1484–1491.
   PubMed Web of Science ®Google Scholar
• MANSFIELD PF, LEE JE, BALCH CM: Cutaneous melanoma: current practice and surgical controversies. In: Current Problems in Surgery Wells SA Jr. (Ed.), Mosby-Year Book, Inc., St. Louis (1994):253–374.
   Google Scholar
• BALCH CM, SOONG S, SHAW HM, MILTON GW: An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Worldwide. Balch CM, Milton GW (Eds.), JB Lippincott Co., Philadelphia (1985):321–352.
   Google Scholar
• BALCH CM, REINTGEN DS, KIRKWOOD JM, HOUGHTON A, PETERS L, ANG KK: Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology DeVita VT Jr., Hellman S, Rosenberg SA (Eds.), JB Lippincott Co., Philadelphia (1997):1947–1994.
   Google Scholar
• MARSONI S, HOTH D, SIMON R, LEYLAND-JONES B, DE ROSA M, WITTES RE: Clinical drug development: an analysis of Phase II trials, 1970-1985. Cancer Treat. Rep. (1987) 71:71–80.
   PubMedGoogle Scholar
• AGARWALA SS, KIRKWOOD JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 5:144–151.
   PubMedGoogle Scholar
• DEL PRETE SA, MAUER LH, O'DONNELL J et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, tamoxifen in metastatic melanoma. Cancer Treat. Rep. (1984) 68:1403–1405.
   PubMedGoogle Scholar
• MCCLAY EF, MASTERANGELO MJ, BELLET RE, BERD D: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer TrearRep. (1987) 71:465–469.
   PubMed Web of Science ®Google Scholar
• MCCLAY EF, MASTERANGELO MJ, SPRANDIO JL et al: The importance of tamoxifen to cisplatin containing regimen in the treatment of metastatic melanoma. Cancer (1989) 63:1292–1295.
   PubMed Web of Science ®Google Scholar
• RUSTHOVEN J, QUIRT I, ISCOE Net al.: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol. (1996) 14:2083–2090.
   Google Scholar
• CHAPMAN PB, EINHORN LH, MEYERS ML et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oiled. (1999) 17(9):2745–2751.
   PubMed Web of Science ®Google Scholar
• •Key paper establishing the ineffectiveness of multi-agent chemotherapy for metastatic melanoma in the context of a large clinical trial.
   Google Scholar
• ROSENBERG SA, GRIMM EA, MC GROGAN M et al: Biological activity of recombinant human interleukin-2 produced in Escherichia coll. Science (1984) 223:1412–1415.
   PubMed Web of Science ®Google Scholar
• LOTZE MT, CHANG AD, SIEPP CA et al.: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. JAMA (1986) 256:3117–3124.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG YC et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210:474–485.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG YC, TOPALIAN SL et al: Treatment of 283 consecutive cancer patients with metastatic melanoma and renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:9007–9013.
   Google Scholar
• DUTCHER JP, CREEKMORE S, WEISS GR et al.: A Phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J. Clin. °ilea (1989) 7:477–485.
   PubMed Web of Science ®Google Scholar
• AGARWALA SS, KIRKWOOD JM: Melanoma immunotherapeutic ipproaches. BioDrugs (1999) 12(3) 193–208.
   PubMedGoogle Scholar
• PARKINSON D, ABRAMS J, WIERNIK P et al.: Interleukin-2 therapy in patients with metastatic malignant melanoma: a Phase II study. j Clin. Oncol. (1990) 8:1650–1656.
   PubMed Web of Science ®Google Scholar
• THATCHER N: Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. Curr. Opin. Oncol. (1991) 3:364–376.
   PubMedGoogle Scholar
• WHITEHEAD RP KOPECKY KJ, SAMSON MK et al.: Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group. j Nati Cancer Inst. 83:1250-1252.
   Google Scholar
• ATKINS MB: The treatment of metastatic melanoma with chemotherapy and biologics. Cum: Opin. Oncol. (1997) 9:207–213.
   Google Scholar
• KIRKWOOD JM, ERNSTOFF M: Potential applications of the interferons in oncology: lessons drawn from studies in human melanoma. Semin. Oncol. (1986) 13:S48–56.
   PubMed Web of Science ®Google Scholar
• CREAGAN ET, AHMANN DL, FRYTAK S, LONG HJ, ITRI LM: Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer (1986) 58:2576–2578.
   Google Scholar
• ROBINSON WA, KIRKWOOD J, HARVEY H, MUGHAL T, MC CUNE C, MUGGIA F: Effective use of recombinant human a-2 interferon (IFN a-2) in metastatic malignant melanoma (MMM): a comparison of two regimens. Proc. Am. Soc. Clin. Ducal. (1984).
   Google Scholar
• ROBINSON WA, MUGHAL TI, THOMAS MR, JOHNSON M, SPIEGEL RJ: Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiol. (1986) 172:275–282.
   PubMed Web of Science ®Google Scholar
• COATES A, RALLINGA M, HERSEY P, SWANSON C: Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. j Interferon Res. (1986) 6:1–4.
   PubMedGoogle Scholar
• DORVAL T, PALANGIE T, JOUVE M et al.: Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b. Invest. New Drugs (1987) 5:S61–63.
   PubMed Web of Science ®Google Scholar
• CHAPMAN PB, PARKINSON D, KIRKWOOD J: Biologic therapy. In: Cutaneous Melanoma. Balch C, Houghton A, Sober A, Soon S-J (Eds.), Quality Medical Publishing, Inc., St. Louis (Edition 3) (1998):419–436.
   Google Scholar
• LEGHA SS: Interferons in the treatment of malignant melanoma. Cancer (1986) 57\(Suppl. 8):1675–1677.
   Google Scholar
• AGARWALA SS, KIRKWOOD JM: Adjuvant interferon treatment for melanoma. Hematol. Oncol. Chu. N Am. (1998) 12:823–833.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP FIGLIN R, CITRON ML et al.: A Phase II trial of concomitant human interleukin-2 and interferon-alpha-2b in patients with disseminated malignant melanoma. j Immunother (1993) 13:117–121.
   Google Scholar
• SPARANO J, FISHER R, SUNDERLAND M etal.: Randomized Phase III trial of treatment with high dose interleukin-2 alone or in combination with interferon alfa-2a in patients with advanced melanoma. J. Clin. Oncol. (1993) 11:1969–1977.
   Google Scholar
• KRUIT W, GOEY S, CALABRESI F etal.: Final report of a Phase II study of interleukin-2 and interferon alpha in patients with metastatic melanoma. Br Cancer (1995) 71(6):1319–1321.
   Google Scholar
• KRUIT W, PUNT C, GOEY S et al.: Doseefficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma. Br .j Cancer (1996) 74(6):951–957.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, CONRADT C, LEGHA SS etal.: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. Clin. Ducal. (1998) 16:2921–2929.
   Google Scholar
• ALLEN I, KUPELNICK B, KUMASHIRO M: Efficacy of interleukin-2 in the treatment of metastatic melanoma: systemic review and metastasis-analysis. Cancer Therapeut. (1998) 1:168–173.
   Google Scholar
• DILLMAN R, OLDHAM R, BARTH N et al.: Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group Trial. Natl. Cancerinst. (1990) 82:1345–1349.
   Google Scholar
• FIEDLER W, JASMIN C, DE MULDER P et al.: A Phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur. Cancer (1992) 28:443–446.
   Google Scholar
• THOMSON D, ADENA M, MC LEOD G et al.: Interferon alpha-2a does not improve response or survival when combined with dacarbazine in metastatic melanoma. Results of a multi-institutional Australian randomized trial. Melanoma Res. (1993) 3:133–138.
   Google Scholar
• FALKSON C, IBRAHIM J, KIRKWOOD J, COATES A, ATKINS M, BLUM R: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with malignant metastatic melanoma: an Eastern Cooperative Oncology Group study. j Chia. Oncol. (1998) 16(5):1743–1751.
   PubMed Web of Science ®Google Scholar
• RICHARDS J, GALLED, MEHTA N, LESTINGI T: Combination of chemotherapy with IL-2 and IFN-alpha for the treatment of metastatic melanoma. Oncol. (1999) 17(2):651–657.
   Google Scholar
• ROSENBERG SA, YANG J, SCHWATZENTRUBER D et al.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with IL-2 and IFN-alpha-2b. I Clin. Oncol. (1999) 17(3):968–975.
   PubMed Web of Science ®Google Scholar
• ROWE JM: Treatment of acute myelogenous leukemia in older adults. Leukemia (2000) 14(3):480–487.
   PubMed Web of Science ®Google Scholar
• VOLM MD, TALLMAN MS: Developments in the treatment of acute leukemia in adults. Curr. Opin. Oncol. (1995) 7:28–35.
   PubMedGoogle Scholar
• MARGOLIN K, FORMAN SJ: Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Cancer I Sri. Am. (2000) 6(Suppl.):533–538.
   Google Scholar
• LOWENBERG B, SUCUI A, ARCHIMBAUD E et al.: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly. J. Clin. Ducal. (1998) 16:872–881.
   PubMed Web of Science ®Google Scholar
• GREER JP, KINNEY MC: Acute nonlymphocytic leukemia. In: Wintrobei Clinical Hematology Lee RG, Bithell TC, Foerster J, Athens JW, Lukens JN (Eds.), Lea & Febiger, Malvern (Edition 9) (1993):1920–1945.
   Google Scholar
• RANDOLPH GJ, BEAULIEU S, POPE M et al.: A physiologic function of P-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Nati Acad. Li. USA (1998) 95(12):6924–6929.
   PubMed Web of Science ®Google Scholar
• ROWLEY JD, ALIMENA G, GARSON OM etal.: A collaborative study of the 878 relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood (1982) 59(5):1013–1022.
   Google Scholar
• BLOOMFIELD CD, LAWRENCE D, BYRD JC et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. (1998) 58(18):4173–4179.
   PubMed Web of Science ®Google Scholar
• YATES J, GLIDEWELL 0, WIERNIK P et al.: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 60:454–462.
   Google Scholar
• •Phase II study of subcutaneous IL-2 in acute myelogenous leukaemia.
   Google Scholar
• BERMAN E, HELLER G, SANTORSO J et al.: Results of a randomized trial comparing idarubicin and cytosine and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood (1991) 77(8):1666–1674.
   PubMed Web of Science ®Google Scholar
• SHEPARD JD, JACKY E, GRATWOHL A et al.: Phase II study of subcutaneous rHU interleukin-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br j Haematol. (1994) 87:205. Abstract.
   Google Scholar
• THALHAMMER E GEISSLER K, JAGER U et al.: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann. Hematol (1996) 72:216–222.
   PubMed Web of Science ®Google Scholar
• MELONI G, VIGNETTI M POGLIANI E et al: Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer I Sri. Amer. (1997) 3:S43–47.
   Web of Science ®Google Scholar
• BRUNE M, HELLSTRAND K: Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br j Haematol (1996) 92(3):620–626.
   PubMed Web of Science ®Google Scholar
• HELLSTRAND K, MELLQVIST UH, WALLHULT E et al.: Histamine and interleukin-2 in acute myelogenous leukemia. Leuk. Lymphoma (1997) 27:429–438.
   PubMed Web of Science ®Google Scholar
• HELLSTRAND K, NAREDI E LINDNER P et al: Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immuriol. Immuriother (1994) 39:416–419.
   PubMed Web of Science ®Google Scholar
• NAREDI P, LINDNER E EHLSEN K, HELLSTRAND K: Increased survival of patients with malignant melanoma liver metastases treated with Maxamine'm (histamine dihydrochloride), interleukin-2 and interferon-a 2b. Proc. Am. Soc. Clin. Oricol. (1999) 18:552a. Abstract.
   Google Scholar
• AGARWALA SS, GLASPY J, O'DAY SJ et al.: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. j Clin. Oricol (2001) (In press). Original report of the first randomised trial of IL-2 plus histamine vs. IL-2 alone for metastatic melanoma.
   Google Scholar
• GLASPY J, O& DAY S, WHITMAN E et at.: The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared to interleukin-2 alone in patients with metastatic melanoma. Melanoma Res. (2001) 11\(Suppl. 1):S124 Abstract.
   Google Scholar
• SHAYER RW, COOPER JAD: Metabolism of 14C-histamine in man. I Appl. Physiol (1956) 9:481.
   PubMed Web of Science ®Google Scholar
• STOCKENHUBER F, SUNDER-PLASSMANN G, BALCKE P: Increased plasma histamine levels in chronic renal failure [letter]. N Eng] j Med. (1987) 317:386.
   PubMed Web of Science ®Google Scholar